DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2010/024.0622 A1 Garvey (43) Pub

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2010/024.0622 A1 Garvey (43) Pub US 2010O240622A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/024.0622 A1 Garvey (43) Pub. Date: Sep. 23, 2010 (54) NITRICOXIDE ENHANCING Publication Classification PROSTAGLANDIN COMPOUNDS, (51) Int. Cl. COMPOSITIONS AND METHODS OF USE A6II 3/56 (2006.01) C07D 271/08 (2006.01) A6II 3/42.45 (2006.01) (75) Inventor: David S. Garvey, Dover, MA (US) A6IP27/02 (2006.01) A6IPI3/08 (2006.01) A6IP 9/00 (2006.01) Correspondence Address: A6IPL/04 (2006.01) WILMERHALEANTROMED A6IP 5/04 (2006.01) 1875 PENNSYLVANIAAVE, NW C07D 413/04 (2006.01) WASHINGTON, DC 20006 (US) A 6LX 3/5.377 (2006.01) A63L/454 (2006.01) C07D 265/06 (2006.01) (73) Assignee: NITROMED, INC., Laxington, A 6LX 3/535 (2006.01) MA (US) A 6LX 3/55.75 (2006.01) CD7C 403/10 (2006.01) (52) U.S. Cl. ......... 514/171; 548/125; 514/364; 54.4/138: (21) Appl. No.: 12/294,642 514/236.2:546/210: 514/326; 544/97: 514/228.8; 514/573; 562/503 (22) PCT Fled: Mar. 19, 2007 (57) ABSTRACT The invention provides compositions and kits comprising at least one nitric oxide enhancing prostaglandin compound ora (86) PCT NO.: PCT/US2007/006749 pharmaceutically acceptable Salt thereof, and, optionally, at least one nitric oxide enhancing compound and/or at least one S371 (c)(1), therapeutic agent. The invention also provides methods for (2), (4) Date: Sep. 26, 2008 (a) treating ophthalmic disorders; (b) treating cerebrovascu lar disorders; (c) treating cardiovascular disorders; (d) treat ing benign prostatic hyperplasia (BPH); (e) treating peptic Related U.S. Application Data ulcers; (e) treating sexual dysfunctions and (f) inducing abor tions. The nitric oxide enhancing prostaglandin compounds (60) Provisional application No. 60/786,689, filed on Mar. comprise at least one heterocyclic nitric oxide donor group 29, 2006. and/or at least one nitroxide group. US 2010/024.0622 A1 Sep. 23, 2010 NITRC OXDE ENHANCING example, S-nitrosothiols, nitrites, nitrates, N-oxo-N-nitro PROSTAGLANDIN COMPOUNDS, samines, furoxans, sydnonimines, SPM 3672, SPM 4757, COMPOSITIONS AND METHODS OF USE SPM 5185, SPM 5186 and analogues thereof, substrates of the various isozymes of nitric oxide synthase, and nitroxides. RELATED APPLICATIONS Thus, another embodiment of the invention provides compo 0001. This application claims priority under 35 USC S119 sitions comprising at least one nitric oxide enhancing pros to U.S. Application No. 60/786,689 filed Mar. 29, 2006; the taglandin compound and at least one nitric oxide enhancing disclosure of which is incorporated by reference herein in its compound. The invention also provides for Such composi entirety. tions in a pharmaceutically acceptable carrier. 0006. The invention provides compositions comprising at FIELD OF THE INVENTION least one nitric oxide enhancing prostaglandin compound, and, optionally, at least one nitric oxide enhancing compound 0002 The invention describes compositions and kits com and/or at least one therapeutic agent, including, but not lim prising at least one nitric oxide enhancing prostaglandin com ited to, aldosterone antagonists, C.-adrenergic receptor ago pound or a pharmaceutically acceptable salt thereof, and, nists, C.-adrenergic receptor antagonists, B-adrenergic ago optionally, at least one nitric oxide enhancing compound nists, antidiabetic compounds, antimicrobial compounds, and/or at least one therapeutic agent. The invention also pro antihyperlipidemic drugs, angiotensin II antagonists, angio vides methods for (a) treating ophthalmic disorders; (b) treat tensin-converting enzyme (ACE) inhibitors, antioxidants, ing cerebrovascular disorders; (c) treating cardiovascular dis antithrombotic and vasodilator drugs, B-adrenergic antago orders; (d) treating benign prostatic hyperplasia (BPH); (e) nists, calcium channel blockers, carbonic anhydrase inhibi treating peptic ulcers; (e) treating sexual dysfunctions and (f) tors, diuretics, endothelin antagonists, hydralazine com inducing abortions. The nitric oxide enhancing prostaglandin pounds, H2 receptor antagonists, neutral endopeptidase compounds comprise at least one heterocyclic nitric oxide inhibitors, nonsteroidal antiinflammatory compounds donor group and/or at least one nitroxide group. (NSAIDs), phosphodiesterase inhibitors, potassium channel blockers, platelet reducing agents, prostaglandins, proton BACKGROUND OF THE INVENTION pump inhibitors, renin inhibitors, selective cyclooxygenase-2 0003 Most drugs conventionally used to treat ophthalmic (COX-2) inhibitors, steroids, compounds used for the treat disorders have potentially serious side effects Such as blurring ment of glaucoma, and combinations of two or more thereof. of vision and other visual side effects which may lead either The invention also provides for such compositions in a phar to decreased patient compliance or to the termination of maceutically acceptable carrier. therapy. Occasionally systemically administered drugs can 0007 Another embodiment of the invention provides also cause serious side effects, such as nausea, dyspepsia, compositions comprising at least one nitric oxide enhancing fatigue, and metabolic acidosis, which affect patient compli prostaglandin compound, and at least one therapeutic agent ance and/or necessitate the termination of treatment. Addi selected from the group consisting of an O-adrenergic recep tionally, Some B-adrenergic antagonists have increasingly tor antagonist, a B-adrenergic agonist, an antimicrobial com become associated with serious pulmonary side effects attrib pound, a B-adrenergic antagonist, a calcium channel blocker, utable to their effects on B-2 receptors in pulmonary tissue. a carbonic anhydrase inhibitor, a nonsteroidal antiinflamma Hence there is a need in the art for compounds that have tory compound (NSAID), a phosphodiesterase inhibitor, a improved efficacy, lower toxicity and/or fewer side effects potassium channel blocker, a prostaglandin, a proton pump and that can be used at low dosages. The invention is directed inhibitor, a selective cyclooxygenase-2 (COX-2) inhibitor, a to these, as well as other, important ends. steroid, a compound used for the treatment of glaucoma, and combinations of two or more thereof. The invention also SUMMARY OF THE INVENTION provides for Such compositions in a pharmaceutically accept 0004. The invention provides novel nitric oxide enhancing able carrier. prostaglandin compounds that are Substituted with at least 0008. The invention provides methods for(a)treating oph one heterocyclic nitric oxide donor group and/or at least one thalmic disorders; (b) treating cerebrovascular disorders; (c) nitroxide group and pharmaceutically acceptable salts treating cardiovascular disorders; (d) treating benign pros thereof. The prostaglandin compound can be substituted with tatic hyperplasia (BPH); (e) treating peptic ulcers; (e) treating the heterocyclic nitric oxide donor group and/or the nitroxide sexual dysfunctions and (f) inducing abortions in a patient in group through one or more sites Such as oxygen (hydroxyl need thereof comprising administering to the patient an effec condensation), Sulfur (sulfhydryl condensation) and/or nitro tive amount of at least one nitric oxide enhancing prostaglan gen via a bond or moiety that can be hydrolyzed. The hetero din compound, and, optionally, at least one therapeutic agent, cyclic nitric oxide donors are furoxans, Sydnonimines, Such as, for example, aldosterone antagonists, B-adrenergic oXatriazole-5-ones and/or oxatriazole-5-imines. The inven receptor agonists, C.-adrenergic receptor antagonists, B-adr tion also provides compositions comprising the novel com energic agonists, antidiabetic compounds, antimicrobial pounds described herein in a pharmaceutically acceptable compounds, anti-hyperlipidemic drugs, angiotensin II carrier. antagonists, angiotensin-converting enzyme (ACE) inhibi 0005. The invention is also based on the discovery that tors, antioxidants, antithrombotic and vasodilator drugs, administering at least one nitric oxide enhancing prostaglan B-adrenergic antagonists, calcium channel blockers, carbonic din compound (i.e. heterocyclic nitric oxide donor group anhydrase inhibitors, diuretics, endothelin antagonists, and/or nitroxide group), or a pharmaceutically acceptable salt hydralazine compounds. He receptor antagonists, neutral thereof, and, optionally, at least one nitric oxide enhancing endopeptidase inhibitors, nonsteroidal antiinflammatory compound improves the properties of the prostaglandin com compounds (NSAIDs), phosphodiesterase inhibitors, potas pound. Nitric oxide enhancing compounds include, for sium channel blockers, platelet reducing agents, prostaglan US 2010/024.0622 A1 Sep. 23, 2010 dins, proton pump inhibitors, renin inhibitors, selective dry eye disorder, ocular hypertension, ocular bleeding, retinal cyclooxygenase-2 (COX-2) inhibitors, Steroids, compounds diseases or disorders, presbyopia, macular degeneration, cho used for the treatment of glaucoma, and combinations of two roidal neovascularization (CNV), retinopathies, such as for or more thereof. The methods can optionally further com example, diabetic retinopathy, vitreoretinopathy, and the like, prises the administration of at least one nitric oxide enhancing retinitis, such as for example, cytomegalovirus (CMV) retini compound. In this embodiment of the invention, the methods tis, uveitis, macular edema, neuropathies and the like. can involve (i) administering the nitric oxide enhancing pros 0013 “Ophthalmic infections' include, but are not limited taglandin compounds, (ii)
Load more

Recommended publications
  • The In¯Uence of Medication on Erectile Function
    International Journal of Impotence Research (1997) 9, 17±26 ß 1997 Stockton Press All rights reserved 0955-9930/97 $12.00 The in¯uence of medication on erectile function W Meinhardt1, RF Kropman2, P Vermeij3, AAB Lycklama aÁ Nijeholt4 and J Zwartendijk4 1Department of Urology, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands; 2Department of Urology, Leyenburg Hospital, Leyweg 275, 2545 CH The Hague, The Netherlands; 3Pharmacy; and 4Department of Urology, Leiden University Hospital, P.O. Box 9600, 2300 RC Leiden, The Netherlands Keywords: impotence; side-effect; antipsychotic; antihypertensive; physiology; erectile function Introduction stopped their antihypertensive treatment over a ®ve year period, because of side-effects on sexual function.5 In the drug registration procedures sexual Several physiological mechanisms are involved in function is not a major issue. This means that erectile function. A negative in¯uence of prescrip- knowledge of the problem is mainly dependent on tion-drugs on these mechanisms will not always case reports and the lists from side effect registries.6±8 come to the attention of the clinician, whereas a Another way of looking at the problem is drug causing priapism will rarely escape the atten- combining available data on mechanisms of action tion. of drugs with the knowledge of the physiological When erectile function is in¯uenced in a negative mechanisms involved in erectile function. The way compensation may occur. For example, age- advantage of this approach is that remedies may related penile sensory disorders may be compen- evolve from it. sated for by extra stimulation.1 Diminished in¯ux of In this paper we will discuss the subject in the blood will lead to a slower onset of the erection, but following order: may be accepted.
    [Show full text]
  • Diuretic Cocktail"
    Clinical evaluation of a "diuretic cocktail" LAWRENCE J. GALLA, A.B., D.O., and WIL- acetazoleamide depressing hydration of carbon LIAM BALDWIN, JR., D.O., F.A.C.0.1., York, dioxide, exchange resins drawing salt from food Pennsylvania in the intestinal tract, or water diuresis. Therefore, diuretic therapy should be planned to permit daily salt and water balance. The treatment should take into account the particular type of fluid or electro- The characteristics of an ideal diuretic can be lyte to be removed, the need for speed in its re- easily enumerated; it should be effective without moval, and the setting in which it will be done. producing electrolyte disturbance, nephrotoxicity, Oral diuretics, for example, are desirable; however, sensitivity, refractoriness, or cardiac toxicity. How- they are often not powerful enough for acute or ever, in practice, a compound encompassing these emergency problems, or they may irritate the pa- properties remains to be found. Furthermore, be- tient's stomach. It may be said that oral diuretics cause of the many factors involved in the patho- are useful in cases where a modest diuretic action logic states that result in abnormal water retention, is satisfactory. Other clinical situations are met by a universal diuretic—that is, one that will work in other means. every situation—has yet to to be made available. Diet is rather important. Patients with edema In recent years a number of new diuretic drugs will probably have to accept a low-salt diet sooner utilizing various physiologic principles have ap- or later; the sooner they start, the sooner better peared.
    [Show full text]
  • List of Union Reference Dates A
    Active substance name (INN) EU DLP BfArM / BAH DLP yearly PSUR 6-month-PSUR yearly PSUR bis DLP (List of Union PSUR Submission Reference Dates and Frequency (List of Union Frequency of Reference Dates and submission of Periodic Frequency of submission of Safety Update Reports, Periodic Safety Update 30 Nov. 2012) Reports, 30 Nov.
    [Show full text]
  • Health Reports for Mutual Recognition of Medical Prescriptions: State of Play
    The information and views set out in this report are those of the author(s) and do not necessarily reflect the official opinion of the European Union. Neither the European Union institutions and bodies nor any person acting on their behalf may be held responsible for the use which may be made of the information contained therein. Executive Agency for Health and Consumers Health Reports for Mutual Recognition of Medical Prescriptions: State of Play 24 January 2012 Final Report Health Reports for Mutual Recognition of Medical Prescriptions: State of Play Acknowledgements Matrix Insight Ltd would like to thank everyone who has contributed to this research. We are especially grateful to the following institutions for their support throughout the study: the Pharmaceutical Group of the European Union (PGEU) including their national member associations in Denmark, France, Germany, Greece, the Netherlands, Poland and the United Kingdom; the European Medical Association (EMANET); the Observatoire Social Européen (OSE); and The Netherlands Institute for Health Service Research (NIVEL). For questions about the report, please contact Dr Gabriele Birnberg ([email protected] ). Matrix Insight | 24 January 2012 2 Health Reports for Mutual Recognition of Medical Prescriptions: State of Play Executive Summary This study has been carried out in the context of Directive 2011/24/EU of the European Parliament and of the Council of 9 March 2011 on the application of patients’ rights in cross- border healthcare (CBHC). The CBHC Directive stipulates that the European Commission shall adopt measures to facilitate the recognition of prescriptions issued in another Member State (Article 11). At the time of submission of this report, the European Commission was preparing an impact assessment with regards to these measures, designed to help implement Article 11.
    [Show full text]
  • Prediction of Premature Termination Codon Suppressing Compounds for Treatment of Duchenne Muscular Dystrophy Using Machine Learning
    Prediction of Premature Termination Codon Suppressing Compounds for Treatment of Duchenne Muscular Dystrophy using Machine Learning Kate Wang et al. Supplemental Table S1. Drugs selected by Pharmacophore-based, ML-based and DL- based search in the FDA-approved drugs database Pharmacophore WEKA TF 1-Palmitoyl-2-oleoyl-sn-glycero-3- 5-O-phosphono-alpha-D- (phospho-rac-(1-glycerol)) ribofuranosyl diphosphate Acarbose Amikacin Acetylcarnitine Acetarsol Arbutamine Acetylcholine Adenosine Aldehydo-N-Acetyl-D- Benserazide Acyclovir Glucosamine Bisoprolol Adefovir dipivoxil Alendronic acid Brivudine Alfentanil Alginic acid Cefamandole Alitretinoin alpha-Arbutin Cefdinir Azithromycin Amikacin Cefixime Balsalazide Amiloride Cefonicid Bethanechol Arbutin Ceforanide Bicalutamide Ascorbic acid calcium salt Cefotetan Calcium glubionate Auranofin Ceftibuten Cangrelor Azacitidine Ceftolozane Capecitabine Benserazide Cerivastatin Carbamoylcholine Besifloxacin Chlortetracycline Carisoprodol beta-L-fructofuranose Cilastatin Chlorobutanol Bictegravir Citicoline Cidofovir Bismuth subgallate Cladribine Clodronic acid Bleomycin Clarithromycin Colistimethate Bortezomib Clindamycin Cyclandelate Bromotheophylline Clofarabine Dexpanthenol Calcium threonate Cromoglicic acid Edoxudine Capecitabine Demeclocycline Elbasvir Capreomycin Diaminopropanol tetraacetic acid Erdosteine Carbidopa Diazolidinylurea Ethchlorvynol Carbocisteine Dibekacin Ethinamate Carboplatin Dinoprostone Famotidine Cefotetan Dipyridamole Fidaxomicin Chlormerodrin Doripenem Flavin adenine dinucleotide
    [Show full text]
  • Adverse Effects and Precautions
    1736 Disinfectants and Preservatives i Amylmetacresoi (BAN, riNN) ..................Preparat ons........ Adverse Effects and Precautions ProprietaryPreparations (details are given in Volume B) The alkyl gallates may cause contact sensitivity and skin Aml!metacreso!; A[ililrnetakrezol: Amylrnet.acreso[; Amylrne.­ AM<InM<;· Multi-ingredient Preparations. Singapore: Esemdent. reactions. ta�resolurn; Amylmetakresol: Amyylirnetakresoli; TaKpe30J1. Effects on the blood. Methaemoglobinaemia associated 6-Pentyl-rn,cresol; S;Methyl.-2-pentylpheooi. Alkyl Gallates with the antoxidants (butylated hydroxyanisole, butylated C1 J1,80= 178.3 hydroxytoluene, and propyl gallate) used to preserve the CAS 1300,94-3. .de Gaiatos alquilo; AnKwnrannalJ:>t. oil in a soybean infant feed fom1ula has been reported.1 UN!! -'-· 05W904P57F: Propyl gallate was suspected of being the most likely cause Dodecyl Gallate because its chemical structure is similar to pyrogallol Pharmacopoeias. In Bur. (see p. vii). (p. 1718.2), a methaemoglobinaemia inducer. Ph. Eur. 8: (Amylmetacresol). A clear or almost clear liquid Dodecilo galatas; Dociecyle,. gallate Dodecylgallat; . de; ..•. I. Nitzan M, et al. Infantile methemoglobinemia caused by food additives. or a solid crystalline mass, colourless or slightly yellow Dodecyi-9Jilat; D(0ec%lis (iallas:. Dodekyyligallaattl; E312; Clin Toxicol 1979; 15: 273-80. when freshly prepared; it darkens or discolours to dark m Galata • de dodecflo; Laury! Gailate; Laurylum Gafikw ; yellow, brownish-yellow, or pink on keeping. F.p. about 22 }logel\vfn rarinar. Preparations degrees. Practically insoluble in water; very soluble in Dodecyi 3,4,5-trihyc;lroxybenzoate. ...................... alcohol and in acetone. Store in non�metallic airtight (details are given in Volume B) C;ul;lje0$=338.4 ProprietaryPreparations containers. Protect from light.
    [Show full text]
  • Populationsweite Utilisationsuntersuchung in Den Chronischen Krankheitsbildern Hypertonie, Hyperlipid¨Amieund Typ 2 Diabetes Mellitus –
    Ruhr-Universit¨atBochum Prof. Dr. rer. nat. Hans J. Trampisch Dienstort: Abteilung f¨urMedizinische Informatik, Biometrie und Epidemiologie Populationsweite Utilisationsuntersuchung in den chronischen Krankheitsbildern Hypertonie, Hyperlipid¨amieund Typ 2 Diabetes Mellitus { Eine Studie des Projekts PUKO-BHD an der Medizinischen Universit¨atWien Inaugural-Dissertation zur Erlangung des Doktorgrades der Medizin einer Hohen Medizinischen Fakult¨at der Ruhr-Universit¨atBochum vorgelegt von: Lisanne M. Jandeck aus Herford 2014 Dekan: Prof. Dr. med. Albrecht Bufe Referent: Prof. Dr. rer. nat. Hans J. Trampisch Korreferent: Prof. Dr. med. J¨urgenWindeler Tag der M¨undlichen Pr¨ufung:09.02.2017 Abstract Jandeck Lisanne M. Populationsweite Utilisationsuntersuchung in den chronischen Krankheitsbildern Hypertonie, Hyperlipid¨amieund Typ 2 Diabetes Mellitus Problem: Hypertonie (HT), Hyperlipid¨amie(HL) und Typ 2 Diabetes Mellitus (DM) stellen die h¨aufigstenchronischen Erkrankungen in Osterreich¨ dar, besonders bei Uber-50j¨ahrigen.Die¨ Zielsetzung dieser Teilstudie Utilisation\ des Projekts mit " dem Titel PUKO-BHD { Pr¨avalenz, Utilisation, Kosten und Outcome bei Blut- " hochdruck, Hyperlipid¨amieund Typ 2 Diabetes Mellitus\ ist eine populationsweite epidemiologische Untersuchung zu der Utilisation von Arzneimitteln zur Behand- lung dieser Krankheiten, insbesondere in Bezug auf Mehrfachverschreibungen (dou- ble prescriptions, DP) und Verschreibungen von Kombinationen von Wirkstoffen, die (schwerwiegende) Wechselwirkungen erzeugen k¨onnen (drug-drug
    [Show full text]
  • Ovid MEDLINE(R)
    Supplementary material BMJ Open Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations and Daily <1946 to September 16, 2019> # Searches Results 1 exp Hypertension/ 247434 2 hypertens*.tw,kf. 420857 3 ((high* or elevat* or greater* or control*) adj4 (blood or systolic or diastolic) adj4 68657 pressure*).tw,kf. 4 1 or 2 or 3 501365 5 Sex Characteristics/ 52287 6 Sex/ 7632 7 Sex ratio/ 9049 8 Sex Factors/ 254781 9 ((sex* or gender* or man or men or male* or woman or women or female*) adj3 336361 (difference* or different or characteristic* or ratio* or factor* or imbalanc* or issue* or specific* or disparit* or dependen* or dimorphism* or gap or gaps or influenc* or discrepan* or distribut* or composition*)).tw,kf. 10 or/5-9 559186 11 4 and 10 24653 12 exp Antihypertensive Agents/ 254343 13 (antihypertensiv* or anti-hypertensiv* or ((anti?hyperten* or anti-hyperten*) adj5 52111 (therap* or treat* or effective*))).tw,kf. 14 Calcium Channel Blockers/ 36287 15 (calcium adj2 (channel* or exogenous*) adj2 (block* or inhibitor* or 20534 antagonist*)).tw,kf. 16 (agatoxin or amlodipine or anipamil or aranidipine or atagabalin or azelnidipine or 86627 azidodiltiazem or azidopamil or azidopine or belfosdil or benidipine or bepridil or brinazarone or calciseptine or caroverine or cilnidipine or clentiazem or clevidipine or columbianadin or conotoxin or cronidipine or darodipine or deacetyl n nordiltiazem or deacetyl n o dinordiltiazem or deacetyl o nordiltiazem or deacetyldiltiazem or dealkylnorverapamil or dealkylverapamil
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • Drug and Medication Classification Schedule
    KENTUCKY HORSE RACING COMMISSION UNIFORM DRUG, MEDICATION, AND SUBSTANCE CLASSIFICATION SCHEDULE KHRC 8-020-1 (11/2018) Class A drugs, medications, and substances are those (1) that have the highest potential to influence performance in the equine athlete, regardless of their approval by the United States Food and Drug Administration, or (2) that lack approval by the United States Food and Drug Administration but have pharmacologic effects similar to certain Class B drugs, medications, or substances that are approved by the United States Food and Drug Administration. Acecarbromal Bolasterone Cimaterol Divalproex Fluanisone Acetophenazine Boldione Citalopram Dixyrazine Fludiazepam Adinazolam Brimondine Cllibucaine Donepezil Flunitrazepam Alcuronium Bromazepam Clobazam Dopamine Fluopromazine Alfentanil Bromfenac Clocapramine Doxacurium Fluoresone Almotriptan Bromisovalum Clomethiazole Doxapram Fluoxetine Alphaprodine Bromocriptine Clomipramine Doxazosin Flupenthixol Alpidem Bromperidol Clonazepam Doxefazepam Flupirtine Alprazolam Brotizolam Clorazepate Doxepin Flurazepam Alprenolol Bufexamac Clormecaine Droperidol Fluspirilene Althesin Bupivacaine Clostebol Duloxetine Flutoprazepam Aminorex Buprenorphine Clothiapine Eletriptan Fluvoxamine Amisulpride Buspirone Clotiazepam Enalapril Formebolone Amitriptyline Bupropion Cloxazolam Enciprazine Fosinopril Amobarbital Butabartital Clozapine Endorphins Furzabol Amoxapine Butacaine Cobratoxin Enkephalins Galantamine Amperozide Butalbital Cocaine Ephedrine Gallamine Amphetamine Butanilicaine Codeine
    [Show full text]
  • Pharmaceuticals As Environmental Contaminants
    PharmaceuticalsPharmaceuticals asas EnvironmentalEnvironmental Contaminants:Contaminants: anan OverviewOverview ofof thethe ScienceScience Christian G. Daughton, Ph.D. Chief, Environmental Chemistry Branch Environmental Sciences Division National Exposure Research Laboratory Office of Research and Development Environmental Protection Agency Las Vegas, Nevada 89119 [email protected] Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Why and how do drugs contaminate the environment? What might it all mean? How do we prevent it? Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada This talk presents only a cursory overview of some of the many science issues surrounding the topic of pharmaceuticals as environmental contaminants Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada A Clarification We sometimes loosely (but incorrectly) refer to drugs, medicines, medications, or pharmaceuticals as being the substances that contaminant the environment. The actual environmental contaminants, however, are the active pharmaceutical ingredients – APIs. These terms are all often used interchangeably Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Office of Research and Development Available: http://www.epa.gov/nerlesd1/chemistry/pharma/image/drawing.pdfNational
    [Show full text]